Clinical trials have indicated that nebulized IFN-γ is a viable HDT to help combat Mtb (Dawson et al., 2009; Bharti et al., 2022) and is in clinical trials for sepsis (https://clinicaltrials.gov/study/NCT04990232). This evidence concerns the gene IFNG and Sepsis.